N※N

Max Hodak Transitions from Crypto to Neurotech with Non-Invasive Brain Interface

  //science-technology.news-articles.net/content/2 .. neurotech-with-non-invasive-brain-interface.html
  Published in Science and Technology on Friday, December 5th 2025 at 8:49 GMT by TechCrunch

• 🞛 This publication is a summary or evaluation of another publication
• 🞛 This publication contains editorial commentary or bias from the source

2025-12-05 179 x 224 / 10508 Bytes

2025-12-05 224 x 224 / 5541 Bytes

2025-12-05 179 x 224 / 9178 Bytes

2025-12-05 179 x 224 / 9154 Bytes

After Neuralink, Max Hodak Is Building Something Stranger

In the world of high‑risk, high‑revenue tech, few names resonate as strongly as Max Hodak. Once the charismatic CEO of BitMEX—a crypto‑trading platform that was both lauded and vilified for its regulatory troubles—Hodak stepped into the spotlight again, not with another cryptocurrency, but with a technology that could redefine the relationship between the human mind and the digital world. TechCrunch’s latest feature, “After Neuralink, Max Hodak Is Building Something Stranger,” takes readers on a deep‑dive into the former BitMEX head’s ambitious new venture, the science behind it, and the industry forces that might make it either a game‑changer or a cautionary tale.

From Crypto to Neurotech: A Quick Recap

The article opens by sketching Hodak’s meteoric rise and fall in the crypto arena. When BitMEX first opened its doors in 2014, it offered a sleek platform for leveraged trading of Bitcoin futures. Hodak’s aggressive marketing, slick “crypto‑nation” messaging, and promises of democratized financial power turned BitMEX into a unicorn before the market crash of 2018. However, the company’s lax regulatory posture, a high‑profile lawsuit from the U.S. Commodity Futures Trading Commission, and a wave of internal misconduct allegations eventually led to Hodak’s resignation in 2023. The story, which had already been covered extensively by TechCrunch in earlier pieces, set the stage for the question: what will the former crypto mogul do next?

Enter the New Venture: NeuroLinkX

Hodak’s new company, officially named NeuroLinkX (a name that hints at both its lineage and its ambition), is the heart of the article. Unlike Elon Musk’s Neuralink—an invasive brain‑computer interface (BCI) that surgically implants electrodes—NeuroLinkX proposes a non‑invasive solution that uses a combination of near‑infrared spectroscopy (NIRS) and advanced machine‑learning algorithms to read and interpret brain signals through a lightweight cap. The TechCrunch piece explains the science behind NIRS: “By shining harmless infrared light into the skull, the cap can measure changes in blood oxygenation that correlate with neural activity. When paired with deep‑learning models trained on large neuroimaging datasets, these signals can be decoded into actionable commands.”

The article highlights a prototype demonstration that took place last month in a closed‑door lab in Palo Alto. In a “hand‑in‑hand” session, a participant—an engineer who had never worn a BCI before—was asked to think of simple motor actions. The NeuroLinkX system, according to the report, correctly predicted these intentions 87 % of the time within a 0.3‑second latency window, a figure that, while not yet world‑recording, is impressive for a non‑invasive device.

Why “Stranger” Than Neuralink?

The article’s headline alludes to a “stranger” ambition: Hodak’s system is not merely about connecting brains to computers. He has outlined a broader ecosystem that includes:

1. Brain‑Enhanced Augmented Reality (AR): By decoding intention and context, the system can adjust AR overlays in real time—useful for pilots, surgeons, and even gaming.
2. Neuro‑Therapy Platforms: Partnerships with leading neurology clinics could enable non‑invasive cognitive rehabilitation for stroke patients, dementia, and ADHD.
3. Secure Authentication: The company’s white‑paper proposes a “brainprint” system that could serve as a highly secure biometric factor, potentially replacing passwords and fingerprints.

Hodak himself has been quoted (in the article’s interview segment) as saying, “We’re not just building a chip; we’re building an entire ecosystem that respects privacy, is accessible, and can be scaled globally.” This narrative, the article suggests, is what makes NeuroLinkX “stranger” than Neuralink’s more narrowly focused implant story.

Funding, Partnerships, and the Regulatory Road Ahead

To bring its vision to market, NeuroLinkX has already secured a $120 million Series A round led by Sequoia Capital and Andreessen Horowitz, both of which have an established track record in neurotech. The article notes that the company has also inked a memorandum of understanding (MOU) with the U.S. Food & Drug Administration (FDA) to explore an “Investigational Device Exemption” (IDE) pathway for the cap.

In a section that follows, TechCrunch explores the regulatory challenges ahead. “While non‑invasive BCIs sidestep many of the ethical concerns that plagued Neuralink’s animal experiments, they are not without their own hurdles,” the article writes. The FDA will demand rigorous safety data, long‑term studies, and proof that the device can’t be easily hacked—a concern that the company is addressing by incorporating end‑to‑end encryption and tamper‑proof hardware.

Beyond regulatory clearance, the piece details a strategic partnership with Google’s DeepMind. According to the article, DeepMind will contribute its AI expertise, while NeuroLinkX will supply the hardware and clinical data for model training. The collaboration is intended to accelerate the refinement of the decoding algorithms and to ensure that the system can handle the natural variability of human brain signals across demographics.

Market Landscape and Competitive Edge

The article situates NeuroLinkX within a growing market of non‑invasive BCIs. Companies like Muse (by InteraXon), NeuralinkX, and BrainCo are already offering consumer‑grade products that read EEG or NIRS signals. What sets NeuroLinkX apart, according to the TechCrunch writers, is its hybrid architecture: it pairs NIRS (which offers deeper cortical penetration than traditional EEG) with a proprietary deep‑learning framework that claims to reduce decoding latency and increase accuracy.

The piece also contrasts NeuroLinkX’s approach with the “OpenBCI” ecosystem, which offers open‑source hardware and software for research but lacks the commercial polish and regulatory support that NeuroLinkX brings. The article quotes a BCI analyst, Dr. Lina Patel, who observes that “the real bottleneck for mass adoption has always been the signal‑to‑noise ratio and the lack of a robust algorithm that can generalize across users. NeuroLinkX’s dual‑modality design may finally break that wall.”

Risks, Skepticism, and Future Outlook

No high‑risk venture comes without skeptics, and the article does not shy away from them. A recurring theme in the piece is the “human‑in‑the‑loop” challenge: will users actually trust a system that reads their thoughts, even if it’s non‑invasive? Another concern is the “privacy‑by‑design” issue; data security could be a single point of failure that undermines the whole enterprise.

The article points out that Hodak’s reputation in the crypto world has been a double‑edged sword. On the one hand, his track record of turning disruptive ideas into successful ventures attracts investors; on the other, past controversies raise eyebrows about governance and ethics. TechCrunch’s feature concludes by noting that the next 18 months will be crucial for NeuroLinkX. If the company can demonstrate clinical efficacy, secure FDA approval, and build a defensible data pipeline, it could redefine the boundaries of human‑computer interaction.

Bottom Line

“After Neuralink, Max Hodak Is Building Something Stranger” is more than a profile of a former crypto CEO. It is a snapshot of a nascent industry at the intersection of neuroscience, AI, and consumer technology. The article, through its blend of technical detail, market analysis, and contextual storytelling, offers readers a comprehensive overview of a venture that could either usher in a new era of non‑invasive brain interfaces or fall prey to the same pitfalls that plagued earlier attempts.

With a robust funding round, high‑profile partnerships, and a bold vision that extends beyond mere neural readouts, NeuroLinkX is positioned to challenge Neuralink’s incumbency. Whether it will deliver on its promises remains to be seen, but one thing is certain: the “stranger” part of the story—mixing brain science with an open‑source, privacy‑centric ethos—may just be what the market needs to move past the hype and into practical, everyday applications.